Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272266 | 0.80 | — | — | |
| SCHEMBL4274342 | 0.74 | MAPK1 (0.36) | MAPK1HRH3CYP2A13ALDH1A1SMN1; SMN2 | |
| SCHEMBL4272242 | 0.73 | MAPT (0.42) | MAPK1ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL11773118 | 0.70 | HRH3 (0.40) | HRH3CYP2A13ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4277408 | 0.70 | — | — | |
| SCHEMBL4266616 | 0.70 | CYP19A1 (0.30) | — | |
| SCHEMBL4274445 | 0.69 | KCNH2 (0.40) | ALDH1A1LMNAMAPTKCNJ1MEN1 | |
| SCHEMBL28153702 | 0.69 | KDM4E (0.37) | MAPK1HRH3CYP2A13ALDH1A1SMN1; SMN2 | |
| SCHEMBL4271420 | 0.68 | CYP19A1 (0.35) | — | |
| SCHEMBL11250877 | 0.68 | HRH3 (0.47) | HRH3CYP2A13ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605183-B2 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2009-10-20 | — | — | US | disclosed |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | KOYAMA SHOZO | 2008-08-21 | — | — | US | disclosed |
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2007-03-22 | — | — | US | disclosed |
| EP-0780122-B1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | KOYAMA SHOZO (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6710090-B2 | A CYCLOHEX-1-EN-2-ONE COMPOUND | KOYAMA SHOZO (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6346551-B1 | ANTIBACTERIAL, ANTIFUNGAL, ANTIVIRAL, BACTERICIDAL AND/OR STERILIZATION AGENTS, ANTICANCER DRUGS, BLOOD COAGULATION AND FIBRINOLYSIS INHIBITORS AND/OR BLOCKING AGENTS, INHIBITORY AND/OR BLOCKING AGENTS OF ANTIGEN-ANTIBODY REACTIONS | KOYAMA SHOZO (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-0780122-A1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | Koyama, Shozo (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, SERPINB6, CD74 | MAPK1 1491/4885HRH3 413/4885CYP2A13 2717/4885 |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD69, TFPI, SERPINE1 | MAPK1 163/4885HRH3 4164/4885CYP2A13 3568/4885 |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, MCL1, CD74 | MAPK1 460/4885HRH3 1398/4885CYP2A13 1979/4885 |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | CD47, MCL1, BAK1 | MAPK1 1247/4885HRH3 467/4885CYP2A13 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.